Clinical management of pandemic 2009 influenza A(H1N1) infection

Chest

Volumn 137, Issue 4, 2010, Pages 916-925

  Hui, David S ^a   Lee, Nelson ^a   Chan, Paul K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CORTICOSTEROID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; OSELTAMIVIR; RIBAVIRIN; SIALIDASE INHIBITOR; STEROID; ZANAMIVIR;

ARTICLE; DRUG MEGADOSE; EXTRACORPOREAL OXYGENATION; HEALTH CARE PERSONNEL; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; RISK FACTOR; TIDAL VOLUME;

EID: 77950823495     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2344     Document Type: Article

References (75)

1. Hui DS, Chan PK. Viral pneumonia. In: Laurent GJ, Shapiro SD, eds. Encyclopaedia of Respiratory Medicine. Amsterdam, The Netherlands: Elsevier; 2006:456-466.
2. Smith GJ, Bahl J, Vijaykrishna D, et al. Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci USA. 2009; 106(28):11709-11712.
3. Trifonov V, Khiabanian H, Rabadan R. Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus. N Engl J Med. 2009;361(2):115-119.
4. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med. 2009;360(25):2616-2625.
5. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325(5937):197-201.
6. Maines TR, jayaraman A, Belser JA, et: al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009;325(5939):484-487.
7. Munster VJ, de Wit E, van den Brand JM, et al, Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science, 2009;325(5939):481-483.
8. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization, of new swine-origin H1N1 influenza viruses. Nature. 2009; 460(7258):1021-1025.
9. Khan K, Arino J, Hu W, et al. Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med. 2009;361(2):212-214.
10. World Health Organization. What is phase 6? http://www. who.int;/csr/disease/swineflu/frequently-asked-questions/ levels-pandemic-alert/ en/index.ht:ml. Accessed Sept 20, 2009.
11. World Health Organization. Pandemic (H1N1) 2009-update 77.http://www.who.int/csr/don/2009-12-04/en/index.html. Accessed Dec 8, 2009.
12. Dawood FS, Jain S, Finellli L, et al; Novel Swine-Origin Influenza A (H1N1) Virus Investigation. Team. Emergence of a novel swine-origin influenza A (H1N1.) virus in humans. N Engl J Med. 2009;360(25):2605-2615.
13. World Health Organization. Epidemiological summary of pandemic influenza A (H1N1) 2009 virus - Ontario, Canada, June 2009. Wkly Epidemiol Reo. 2009;84(47):485-491.
14. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al; INER Working Group on. Influenza. Pneumonia and respiratory failure from swine-origin, influenza A (H1N1) in Mexico. N Engl J Med. 2009;361(7):680-689.
15. World Health Organization. Recommended use of antivirals. Pandemic (H1N1) 2009 briefing note 8. http://www.who.int/ csr/disease/swineflu/notes/h1n1-use- antivirals-20090820/en/ index.html. Accessed September 1, 2009.
16. Jain. S, Kamimoto L, Bramley AM, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team, Hospitalized patients with 2009 H1N1 influenza in the United States, April-june 2009. N Engl J Med. 2009;361(20): 1935-1944.
17. Webb SA, Pettilä V, Seppelt I, et al; ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009;361(20): 1925-1934
18. Kumar A, Zarychanski R, Pinto R, et al; Canadian. Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection, in Canada. JAMA. 2009;302(17):1872-1879.
19. World Health Organization. Human infection with pandemic A (H1N1) 2009 influenza virus: clinical observations in hospitalized patients, Americas, July 2009 update. Weekly Epidemiological Record on Pandemic H1N1 2009. 2009;84(30):305-308.
20. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361(20):1945-1952.
21. Garcia-Garcia L, Valdespino-Gómez JL, Lazcano-Ponce E, et al, Partial protection of seasonal, trivalent inactivated vaccine against novel, pandemic influenza A/H1N1 2009: case-control study in. Mexico City. BMJ. 2009;339:b3928.
22. Manad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A. (H1N1) infection. Am J Respir Crit Care Med, 2010;18.1(1):72-79.
23. Centers for Disease Control and Prevention (CDC). Intensivecare patients with severe novel, influenza A (H1N1) virus infection-Michigan, june 2009. MMWR Morb Mortal Wkly Rep. 2009;58(27):749-752.
24. Cheng VC, Lau YK, Lee KL, et al. Fatal co-infection with swine origin influenza virus A/H1N1 and community-acquired methicillin-resistant Staphylococcus aureus. J Inject. 2009; 59(5):366-370.
25. Centers for Disease Control, and Prevention. (CDC). Bacterial. coinfections in lung tissue specimens from fatal, cases of 2009 pandemic influenza A(H1N1)-United States, MayAugust; 2009. MMWR Morb Mortal Wkly Rep. 2009;58(38): 1071-1074
26. Kaufman MA, Duke GJ, McCain F, el; al. Life-threatening respiratory failure from H1N1 influenza 09 (human swine influenza). Med J Aust. 2009;191(3):154-156.
27. Centers for Disease Control and Prevention. (CDC). Evaluation of rapid influenza diagnostic tests for detection of novel, influenza A (H1N1) virus-United States, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(30):826-829.
28. Birnkrant; D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl. J Med, 2009;361(23):2204-2207.
29. GlaxoSmithKline (GSK) and. FDA alert, Relenza (zanamivir) inhalation, powder, http://www.fda.gov/safety/medwatch/ safetyinformation/ safetyalertsforhumanmedicalproducts/ ucm 186081 htm. Accessed October 10, 2009.
30. World Health Organization, Clinical, management of human infection with pandemic (H1N1) 2009: revised, guidance. http://www.who.int/csr/resources/ publications/swineflu/ clinical-management-h1n1.pdf. Accessed November 15, 2009.
31. World Health Organization. Antiviral use and the risk of drug resistance. Pandemic (H1N1) 2009 briefing note 12. http:// www.who.int/csr/disease/ swineflu/notes/h1n1-antiviral-use20090925/en/index.html, Accessed October 2, 2009.
32. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301- 1308.
33. Wiedemann HP, Wheeler AP, Bernard GR, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564-2575.
34. Davies A, Jones D, Bailey M, et al; Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009;302(17):1888-1895.
35. Rello j, Rodríguez A, Ibañez P, et al; H1N1. SEMICYUC Working Group. Intensive care adult patients with severe respiratory failure caused by influenza A (H1N1) in Spain. Crit Care. 2009;13(5):R148.
36. World Health Organization, Infection and control of epidemicand pandemic-prone acute respiratory diseases in health care. WHO interim, guidelines. World Health Organization, 2007. http://www.who.int/csr/resources/ publications/WHO-CD-EPR-2007-6/en/. Accessed Mar 19, 2009.
37. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009; 301(22):2362-2375.
38. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2009;37(5):1594-1603.
39. Quispe-Laime AM, Bracco JD, Barberio PA, et: al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment, Intensive Care Med. 2010;36(1):33-41
40. Lee N, Allen. Chan KC, Hui DS, et al, Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004.;31(4): 304-309. (Pubitemid 39371065)
41. Lee N, Chan. PK, Hui DS, et id. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200(4):492-500.
42. Wang H, Ding Y, Li. X, Yang L, Zhang W, Rang W. Fatal, aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. 2003;349(5):507-508. (Pubitemid 36910035)
43. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology. 2005;235(1): 168-175.
44. Yap FH, Gomersall CD, Fung KS, et al, Increase in methicillinresistant Staphylococcus aureus acquisition rate and change in pathogen pattern, associated with an outbreak of severe acute respiratory syndrome. Clin Infect Dis. 2004;39(4):511-516.
45. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Metaanalysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 145(8):599-609
46. Zhou B, Zhong NS, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450-1451 (Pubitemid 47535608)
47. Lu J, Guo Z, Pan X, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab)2 in mice. Respir Res. 2006;7:43.
48. Hanson Bj, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res. 2006;7:126. (Pubitemid 44642593)
49. de Jong MD, Simmons CP, Thanh TT, et al, Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med, 2006;12(10):1203-1207. (Pubitemid 44527358)
50. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997;112(6 suppl):321S-329S.
51. Bone RC, Grodzin. CJ, Balk RA, Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112(1): 235-243. (Pubitemid 27343624)
52. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6(12): 1399-1402. (Pubitemid 32001026)
53. Fedson DS. Confronting the next: influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses. 2009;3(4): 129-142.
54. Liu Z, Guo Z, Wang G, et al, Evaluation of the efficacy and safety of a statin/caffeine combination, against H5N1, H3N2 and H1N1 virus infection, in BALB/c mice. Eur J Pharm Sci. 2009;38(3):215-223.
55. Clinical management of human infection with avian influenza A (H5N1) virus. WHO updated advice 15 Aug 2007. http:// www.who.int/csr/disease/avian- influenza/guidelines/clinical manage07/en/index.html, Accessed Dec 18, 2007.
56. Lew TW, Kwek TK, Tai D, et al. Acute respiratory distress Syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):374-380. (Pubitemid 37430524)
57. Chong PY, Chui P, Ling AE, et: al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med. 2004;128(2):195-204 (Pubitemid 38155667)
58. Umapathi T, Kor AC, Venketasubramanian N, et: al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227-1231 (Pubitemid 39523114)
59. Han SN, Meydani SN Antioxidants, cytokines, and influenza infection in aged, mice and elderly humans. J Infect: Dis. 2000;.182(Suppl 1):S74-S80.
60. Akaike T, Ando M, Oda T, et al. Dependence on 02-generation. by xanthine oxidase of pathogenesis of influenza virus infection, in mice. J Clin Invest. 1990;85(3):739-745. (Pubitemid 20087476)
61. Knobil. K, Choi AM, Weigand GW, Jacoby DB, Role of oxidants in influenza virus-induced gene expression. Am J Physiol. 1998;274(1 Pt 1):L134-L142.
62. Geiler J, Michaelis M, Naczk P, et: al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of proinflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol. 2010;79(3):413-420.
63. Friel H, Lederman H. A nutritional supplement formula for influenza A (H5N1) infection in humans. Med Hypotheses. 2006;67(3):578-587. (Pubitemid 43928312)
64. Yu IT, Xie ZH, Tsoi KK, et al. Why did outbreaks of severe acute respiratory syndrome occur in some hospital wards but not in others? Clin Infect Dis. 2007;44(8):1017-1025.
65. Lo JY, Tsang TH, Leung YH, Yeung EY, Wu. T, Lim WW. Respiratory infections during SARS outbreak, Hong Kong, 2003. Emerg Infect Dis. 200,5;11(11):1738-1741.
66. World Health Organization. Infection prevention and control in health care for confirmed or suspected cases of pandemic (H1N1) 2009 and influenza-like illnesses. Interim guidance, june 25,2009 (originally published April 29,2009). http://www. who.int/csr/resources/publications/swineflu/swineinfcont/ en/index.html. Accessed Sept: 28,2009.
67. Loeb M, Dafoe N, Mahony j, et al, Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA. 2009;302(17):1865-1871
68. Johnson. DF, Druce JD, Birch C, Grayson. ML. A quantitative assessment of the efficacy of surgical and. N95 masks to filter influenza virus in patients with acute influenza infection. Clin Infect Dis. 2009;49(2):275-277.
69. Hui DS, Chow BK, Ng SS, et al. Fxhaled air dispersion distances during noninvasive ventilation, via different Respironics face masks. Chest. 2009;136(4):998-1005.
70. Hui DS, Chow BK, Chu LC, et al, Exhaled air and aerosolized droplet dispersion, during application, of a jet; nebulizer. Chest. 2009;.135(3):648-654
71. Hui DS, Hall SD, Chan MT, et al. Exhaled air dispersion during oxygen delivery via a simple oxygen, mask. Chest. 2007; 132(2):540-546.
72. Ferguson. NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448-452
73. Yang Y, Sugimoto JD, Halloran ME, et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science. 2009;326(5953):729-733.
74. National. Center for Immunization, and Respiratory Diseases. CDC; Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on. Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58(RR-10):1-8
75. World Health Organization, Experts advise WHO on pandemic vaccine policies and strategies. Pandemic (H1N1) 2009 briefing note 14. http://www.who.int/csr/disease/ swineflu/notes/briefing-20091030/en/index.html. Accessed November 26, 2009.